Cannabis Induces A Clinical Response In Patients With Crohn’s Disease: A Randomized Placebo-Controlled, Double-Blind Study

In the world’s first randomized, placebo-controlled, double-blinded study of its kind, Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results, with 45% of Crohn’s patients achieving “complete remission” and over 90% achieving substantial improvement – with no side effects witnessed.


  • Complete remission (CDAI score <150) was achieved by 5 of the 11 patients in the cannabis group
  • Clinical response (decrease in CDAI score of >100) was observed in 10 of the 11 patients
  • 3 of the 11 patients were weaned from steroid dependency
  • The cannabis group reported significantly less pain, and improved appetite and quality of life


21 patients with Crohn’s Disease Activity Index (CDAI) scores greater than 200, who did not respond to therapy with steroids, immune-modulators, or anti-tumor agents; 11 of the patients were in the cannabis treatment study group, 10 were in the placebo control group